OncRef

Clinical Trial: NCT04609566

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

Status:

COMPLETED

Phase:

Phase 2

Lead Sponsor:Seagen, a wholly owned subsidiary of Pfizer
Information Provided By:Seagen Inc.
Last Update Posted:2026-07-06

Study Overview

Brief Summary

This trial will find out whether brentuximab vedotin and pembrolizumab work together to treat different types of cancer. There will be several different types of cancer studied in the trial. The cancer must have spread to other parts of the body (metastatic).

The study will also find out what side effects occur. A side effect is anything the treatment does besides treat cancer.

This is a multi-cohort study.

Official Title

A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Participants With Metastatic Solid Malignancies

Conditions

Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck

Intervention / Treatment

  • Drug: brentuximab vedotin
  • Drug: pembrolizumab

Other Study ID Numbers

  • SGN35-033
  • C5691005

Start Date (Actual)

2021-01-26

Primary Completion Date (Actual)

2026-02-03

Study Completion Date (Actual)

2026-02-03

Enrollment (Actual)

161

Study Type

Interventional

Phase

Phase 2